Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Teva Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: yosi s who wrote (151)	2/10/1998 10:00:00 PM
From: LLLefty	Read Replies (1) \| Respond to of 340

Lacking a crystal ball, I have no firm view on whether it will bounce soon. Yet, my instinct, a careful reading of the press release and, like you, a long-time admirer of Teva's management kept me from taking my one-point-plus profit on my buy yesterday. Some months ago, I found my way into an MS sufferers thread and found that, on balance, copaxone got better reviews than did its two major competitors. The cost, of course, is enormous and a question most raised was whether insurance would cover the therapy. One nagging concern was that the loss of the Merck distributorship in Israel may have hurt Teva more than it admitted at the time.